Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
Isabelle Mahé, Head of Internal Medicine at Louis Mourier Hospital, APHP at Paris Cité University, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Bleeding risk varies according to solid cancer site, with a low risk of CRB in breast cancer (6·2%) and a narrow range across other solid tumours (15·4–18·5%) (original Article recently published in The Lancet Haematology)
Please read our reply just published in The Lancet Haematology!
In patients with CAT receiving extended treatment, reduced-dose apixaban is non inferior to full dose apixaban, and is associated with a significant 25% reduction in the risk of Clinically Relevant Bleeding (APICAT study published in NEJM Group)”
Title 1: Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Authors: Isabelle Mahé, Céline Chapelle, Philippe Girard, Marc Carrier, Luis Jara Palomares, Charles-Marc Samama, Hélène Helfer, Grigoris Gerotziafas, Silvy Laporte, Eric Vicaut, Patrick Mismetti
Read the Full Article on The Lancet Haematology
Title 2: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J. López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V. Huisman, Frederikus A. Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T. Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte
Read the Full Article on NEJM
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 19, 2026, 08:20Cory Dugan: The IRONWOMAN Trial Individual Responses to IV Iron Therapy in Active Women
-
Oct 19, 2026, 07:36Johannes Kaesmacher: Cerebral No-Reflow After Thrombectomy Toward a Standardized Definition
-
Oct 19, 2026, 07:33Beth Psaila: Highlights from IACH Annual Meeting and MPN Horizons
-
Oct 19, 2026, 07:29Wolfgang Miesbach: Can Losartan Activate Brown Fat? – Nature Study Explores New Therapeutic Link
-
Oct 19, 2026, 07:22Ruben Mesa: Honored to Speak at the Tandem MPN Meetings of IACH
-
Oct 19, 2026, 07:19Saneha Anjum Shaikh: Parul University Partners with Raktasevak Bike Ride 2026 for Blood Donation Drive
-
Oct 19, 2026, 07:09Alejandro González Veliz: No ST Elevation Does Not Guarantee an Open Coronary Artery
-
Oct 19, 2026, 06:02Thomas Dayspring: Vascular Resilience – What Is It and How Can We Measure It?
-
Oct 19, 2026, 05:53Kevon Dindial: Collaboration for Better Childhood Cancer Outcomes